Literature DB >> 2214019

The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation.

R Bartenschlager1, M Junker-Niepmann, H Schaller.   

Abstract

Encapsidation of the pregenomic RNA into nucleocapsids is a selective process which depends on specific RNA-protein interactions. The signal involved in the packaging of the hepatitis B virus (HBV) RNA pregenome was recently defined as a short sequence located near the 5' end of that molecule (Junker-Niepmann et al., EMBO J., in press), but it remained an open question which viral proteins are required. Using a genetic approach, we analyzed whether proteins derived from the HBV P gene play an important role in pregenome encapsidation. The results obtained with point mutations, deletions, and insertions scattered throughout the P gene clearly demonstrate that (i) a P gene product containing all functional domains is required both for the encapsidation of HBV pregenomic RNA and for packaging of nonviral RNAs fused to the HBV encapsidation signal, (ii) known enzymatic activities are not involved in the packaging reaction, suggesting that P protein is required as a structural component, and (iii) P protein acts primarily in cis, i.e., pregenomic RNAs from which P protein is synthesized are preferentially encapsidated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214019      PMCID: PMC248581     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  cis rescue of a mutated reverse transcriptase gene of human hepatitis B virus by creation of an internal ATG.

Authors:  S Roychoudhury; C Shih
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

2.  Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity.

Authors:  G Radziwill; W Tucker; H Schaller
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D.

Authors:  J G Levin; P M Grimley; J M Ramseur; I K Berezesky
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

4.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

5.  Adenovirus DNA replication in vitro: characterization of a protein covalently linked to nascent DNA strands.

Authors:  M D Challberg; S V Desiderio; T J Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template.

Authors:  M J Zoller; M Smith
Journal:  DNA       Date:  1984-12

7.  Signals regulating hepatitis B surface antigen transcription.

Authors:  R Cattaneo; H Will; N Hernandez; H Schaller
Journal:  Nature       Date:  1983 Sep 22-28       Impact factor: 49.962

8.  High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections.

Authors:  A Shields; W N Witte; E Rothenberg; D Baltimore
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

9.  Hepatitis B virus genes and their expression in E. coli.

Authors:  M Pasek; T Goto; W Gilbert; B Zink; H Schaller; P MacKay; G Leadbetter; K Murray
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

10.  Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.

Authors:  F Galibert; E Mandart; F Fitoussi; P Tiollais; P Charnay
Journal:  Nature       Date:  1979-10-25       Impact factor: 49.962

View more
  151 in total

1.  Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses.

Authors:  E V Gazina; J E Fielding; B Lin; D A Anderson
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Distinct requirement for two stages of protein-primed initiation of reverse transcription in hepadnaviruses.

Authors:  Xingtai Wang; Jianming Hu
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  The majority of duck hepatitis B virus reverse transcriptase in cells is nonencapsidated and is bound to a cytoplasmic structure.

Authors:  E Yao; Y Gong; N Chen; J E Tavis
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90.

Authors:  J Hu; D Anselmo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Interaction between hepatitis B virus core protein and reverse transcriptase.

Authors:  L Lott; B Beames; L Notvall; R E Lanford
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus.

Authors:  M Kann; W H Gerlich
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Distinct requirements for primary sequence in the 5'- and 3'-part of a bulge in the hepatitis B virus RNA encapsidation signal revealed by a combined in vivo selection/in vitro amplification system.

Authors:  A Rieger; M Nassal
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

8.  Insertions within the hepatitis B virus capsid protein influence capsid formation and RNA encapsidation.

Authors:  B Beames; R E Lanford
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Transfer of the minus strand of DNA during hepadnavirus replication is not invariable but prefers a specific location.

Authors:  D D Loeb; R Tian
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation.

Authors:  J R Pollack; D Ganem
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.